Back to results
US 2021/0069296 A1Published application
Treatment of pyroptosis
OwnerRajiv JALAN, Ugo SOFFIENTINI +2inventors
InventorsRajiv JALAN, Ugo SOFFIENTINI, Nigel BEATON, Gautam MEHTA
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerRajiv JALAN, Ugo SOFFIENTINI +2inventors
InventorsRajiv JALAN, Ugo SOFFIENTINI, Nigel BEATON, Gautam MEHTA
Estimating the term…
The present invention derives from the unexpected finding that pyroptosis is a novel biomarker and target for therapy in liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). Gasdermin D (GSDMD), caspase 4, caspase 5, or Interleukin 1 alpha (IL-1α) can be detected and quantified in serum or plasma, and used as biomarkers for outcome in liver failure such as acute liver failure (ALF) and ACLF and other diseases involving aberrant pyroptosis. By antagonising GSDMD, caspase 4, caspase 5 or Interleukin 1 alpha (IL-1α) many of the unwanted consequences or symptoms of liver failure such as acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) may be reduced. The present invention utilises these findings to identify and provide antagonists of GSDMD, caspase 4, caspase 5 or IL-1α that may be used in the treatment or prevention of liver failure such as acute liver failure (ALF) and ACLF. The present invention utilises these findings to identify and provide antagonists of GSDMD, caspase 4, caspase 5 or IL-1α that may be used in the treatment or prevention of aberrant pyroptosis in the kidney, brain, liver or other organ of the body.
1-10. (canceled)
A method of diagnosing liver failure, of predicting liver failure or of identifying a patient suitable for treatment of liver failure, the method comprising:
(canceled)
(canceled)
A method of identifying an agent suitable for use in treating or preventing liver failure, the method comprising determining whether a test agent is capable of decreasing the amount or activity of GSDMD, caspase 4, caspase 5 or IL-1α, wherein the ability to decrease the amount or activity of GSDMD, caspase 4, caspase 5 or IL-1α indicates that the compound may be suitable for use in treating liver failure.
18-24. (canceled)
(canceled)
A method of treating or preventing liver failure in an individual in need thereof, said method comprising a step of administering to said individual an antagonist of GSDMD, caspase 4, caspase 5 or IL-1α.
Dependencies are inferred from the claim text.